CanVeer Biopharma Accepted Into Prestigious Intellectual Property Ontario (IPON) Program to Advance IP Strategy for Neonatal Therapy
CanVeer has been accepted into the highly competitive & prestigious Intellectual Property Ontario (IPON) Program. Through IPON CanVeer is eligible to receive up to CAD $300,000 in lifetime funding (on an 80% cost-share basis) to strengthen its intellectual property portfolio for its lead asset AlveoShield™. The program also grants access to expert advisory services in IP strategy, commercialization, training, and portfolio development. - January 28, 2026
CanVeer Biopharma Launches Validation Program for Flagship Neonatal Therapeutic and Appoints Executive Team
CanVeer announces the launch of the validation program for its flagship product, AlveoShield™ (Investigational New Drug). The program targets preterm newborns with or at risk of developing bronchopulmonary dysplasia (BPD). Bronchopulmonary dysplasia is a chronic respiratory disease affecting preterm neonates who require assisted ventilation. AlveoShield™ is designed to potentially prevent and treat BPD. CanVeer also announces the appointment of Sherif Louis as CEO and Behzad Yeganeh as CSO. - January 13, 2026